StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30508% above fair value
$199.33+2.54 (+1.29%)

Close on Nov 19, 2026Market cap $79.58BP/E –Yield –

Moderna Minimum unconditional purchase obligations by Year

Minimum unconditional purchase obligations — Clinical & R&D service contracts ($M) ($M)

Moderna Minimum unconditional purchase obligations: $1,000M in FY2025, up 323.7% from a year earlier.

Latest, FY2025
1,000
Period ended Dec 31, 2025
Change on a year earlier
+323.7%
236 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-20) ↗

Reported in Form 10-K Note 11 (Commitments and Contingencies).

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedMinimum unconditional purchase obligations — Clinical & R&D service contracts ($M) ($M)Year on yearSource
FY2025Dec 31, 20251,000+323.7%Form 10-K (filed 2026-02-20) ↗
FY2024Dec 31, 2024236-9.6%Form 10-K (filed 2025-02-21) ↗
FY2023Dec 31, 2023261+47.5%Form 10-K (filed 2024-02-23) ↗
FY2022Dec 31, 2022177+98.9%Form 10-K (filed 2023-02-24) ↗
FY2021Dec 31, 202189+229.6%Form 10-K (filed 2022-02-25) ↗
FY2020Dec 31, 202027–Form 10-K (filed 2021-02-26) ↗

Cite this data

StockData. (2026). Moderna Minimum unconditional purchase obligations ($M), annual FY2020–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/purchase-commit-clinical

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.

See a number that looks wrong?